Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced it received written feedback from the U.S. Food and Drug Administration following a recent ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE